跳转至内容
Merck
所有图片(1)

主要文件

NIST8671

NISTmAb, 人源化IgG1k单克隆抗体

NIST® SRM® 8671

登录查看公司和协议定价
所有图片(1)

About This Item

UNSPSC代码:
41116107
NACRES:
NA.41

抗体产品类型

primary antibodies

等级

certified reference material

表单

liquid

制造商/商品名称

NIST®

技术

UV/Vis spectroscopy: suitable
liquid chromatography (LC): suitable
mass spectrometry (MS): suitable

包装形式

matrix material

相关类别

一般描述

NISTmAb，人源化IgG1k 单克隆抗体，是一种在鼠悬液培养物中表达的重组抗体。它是具有两个相同的轻链和两个相同的重链的同型二聚体，它们通过链间和链内二硫键进行连接，分子量为150 kDa。该蛋白质具有低丰度的翻译后修饰，包括蛋氨酸氧化、脱酰胺和糖基化。该人源化单克隆抗体还具有N末端焦谷氨酸、C末端赖氨酸剪切和重链糖基化。

一单位RM 8671 由一个含800 µL 10 mg/mL NIST IgG1κ单克隆抗体（NISTmAb）、12.5 mmol/L L-组氨酸和L-组氨酸盐酸盐（pH 6.0）的冷冻管组成。

SRM 8671_Cert

SRM 8671 _SDS

应用

NISTmAb，人源化IgG1k 单克隆抗体已作为标准品，用于在自底向上质谱中对 从头 测序算法进行测试。本标准物质（RM）主要用于评估单克隆抗体生理化学和生物物理属性测定方法的效果。它还为开发治疗性蛋白质表征的新技术提供了代表性的测试分子。其他潜在用途包括：
  • 系统适用性测试、
  • 方法建立或仪器性能和可变性测定、
  • 比较变化的分析测试方法以及
  • 协助方法鉴定。

分析说明

NIST8671供研究使用。不适用于动物或人类食用、临床测试或治疗用途。

其他说明

  • RM 8671用于研究用途。
  • 有关失效日期、储存、安全性、使用和来源的详细信息见于NIST 证书。 
  • 有关生物材料、处置和运输的信息见于SDS。

法律信息

NIST is a registered trademark of National Institute of Standards and Technology
SRM is a registered trademark of National Institute of Standards and Technology

未找到合适的产品？  

试试我们的产品选型工具.

相关产品

产品编号
说明
价格

储存分类代码

12 - Non Combustible Liquids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ioannis Karageorgos et al.
Biologicals : journal of the International Association of Biological Standardization, 50, 27-34 (2017-10-03)
Monoclonal antibody pharmaceuticals are the fastest-growing class of therapeutics, with a wide range of clinical applications. To assure their safety, these protein drugs must demonstrate highly consistent purity and stability. Key to these objectives is higher order structure measurements validated
Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery.
Sen K I, et al.
Journal of the American Society For Mass Spectrometry, 28(5), 803-810 (2017)

商品

An Optimized Protocol for Peptide Mapping of Therapeutic Monoclonal Antibodies with Minimum Deamidation and Oxidation Artifacts

An optimized peptide mapping protocol using NISTmAb as a model monoclonal antibody, shorter incubation times, and improved digestion buffer to demonstrate minimal artificial asparagine deamidation and methionine oxidation.

An Optimized Protocol for Peptide Mapping of Therapeutic Monoclonal Antibodies with Minimum Deamidation and Oxidation Artifacts

An optimized peptide mapping protocol using NISTmAb as a model monoclonal antibody, shorter incubation times, and improved digestion buffer to demonstrate minimal artificial asparagine deamidation and methionine oxidation.

An Optimized Protocol for Peptide Mapping of Therapeutic Monoclonal Antibodies with Minimum Deamidation and Oxidation Artifacts

An optimized peptide mapping protocol using NISTmAb as a model monoclonal antibody, shorter incubation times, and improved digestion buffer to demonstrate minimal artificial asparagine deamidation and methionine oxidation.

An Optimized Protocol for Peptide Mapping of Therapeutic Monoclonal Antibodies with Minimum Deamidation and Oxidation Artifacts

An optimized peptide mapping protocol using NISTmAb as a model monoclonal antibody, shorter incubation times, and improved digestion buffer to demonstrate minimal artificial asparagine deamidation and methionine oxidation.

查看所有结果

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持